Immunology: turning basic research into a therapy.

Immunol Lett

Discovery BioScience, AstraZeneca R and D Charnwood, Bakewell Road Loughborough, LE11 5RH, UK.

Published: June 2005

One of the driving forces in the field of immunology is the ambition to translate experimental research into novel useful therapies. Therefore, the aim of this mini-review is to exemplify emerging therapies as well as highlight hurdles that need to be overcome before they can be introduced into the clinic.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.imlet.2004.12.011DOI Listing

Publication Analysis

Top Keywords

immunology turning
4
turning basic
4
basic therapy
4
therapy driving
4
driving forces
4
forces field
4
field immunology
4
immunology ambition
4
ambition translate
4
translate experimental
4

Similar Publications

Nanolabels for biosensors based on lateral flow immunoassays.

Anal Chim Acta

February 2025

Department of Physical and Analytical Chemistry & Institute of Biotechnology of Asturias, University of Oviedo, c/Julián Clavería 8, 33006, Oviedo, Spain. Electronic address:

The COVID-19 outbreak was an important turning point in the development of a new generation of biosensing technologies. The synergistic combination of an immunochromatographic test (lateral flow immunoassays, LFIA) and signal transducers provides enhanced sensitivity and the ability to quantify in the rapid tests. This is possible due to the variety of nanoparticles that can be used as reporter labels.

View Article and Find Full Text PDF

The treatment landscape for advanced melanoma has transformed significantly with the advent of BRAF and MEK inhibitors (BRAF/MEKi) targeting V600 mutations, as well as immune checkpoint inhibitors (ICI) like anti-PD-1 monotherapy or its combinations with anti-CTLA-4 or anti-LAG-3. Despite that, many patients still do not benefit from these treatments at all or develop resistance mechanisms. Therefore, prognostic and predictive biomarkers are needed to identify patients who should switch or escalate their treatment strategies or initiate an intensive follow-up.

View Article and Find Full Text PDF

Background: Aerobic vaginitis (AV) is a state of abnormal vaginal microbiota, which is associated with increased numbers of aerobic, enteric bacteria and inflammation of the vaginal epithelium. Anti-microbial treatment combined with anti-inflammatory therapy could be useful in the treatment of this condition. It is known that calcitriol, the active form of vitamin D, plays an important role in modulating the immune response in several inflammatory diseases.

View Article and Find Full Text PDF

A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer.

Cancer Cell

January 2025

Cancer Systems Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Centre for Cancer Evolution, Bart's Cancer Institute, Queen Mary University London, London EC1M 6AU, UK. Electronic address:

Fewer than 50% of metastatic deficient mismatch repair (dMMR) colorectal cancer (CRC) patients respond to immune checkpoint inhibition (ICI). Identifying and expanding this patient population remains a pressing clinical need. Here, we report that an interferon-high immunophenotype locally enriched in cytotoxic lymphocytes and antigen-presenting macrophages is required for response.

View Article and Find Full Text PDF

Varicella, a highly contagious disease caused by the varicella-zoster virus (VZV), remains prevalent in China despite the introduction of the varicella vaccine in 1997. The current vaccination protocol in China involves a voluntary, self-funded single-dose regimen. This study aims to investigate the longevity of immune response in Chinese children following two-dose varicella vaccination administered at different intervals, with the objective of optimizing vaccination strategies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!